PolyPeptide publishes invitation to the annual General Meeting 2023
/ Key word(s): AGMEGM
At the AGM 2023, all six current members of the Board of Directors will stand for re-election. Peter Wilden is proposed for re-election as Chairman of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee. As announced on 14 March 2023, the Board of Directors further proposes Dorothee A. Deuring for election as new independent member of the Board of Directors, and upon election it is expected that Ms. Deuring will join the Audit and Risk Committee.
Pursuant to the revised Swiss corporate law that entered into force on 1 January 2023, Swiss corporations are obliged to revise their articles of association within two years to comply with the new law. The Board of Directors proposes to the AGM 2023 various amendments to the Company’s Articles of Association to align with and make use of the increased flexibility provided by the new law. The Board of Directors is also proposing to take this opportunity to align the Articles of Association with current best corporate governance practices in the Swiss market as well as to make some formal changes to facilitate the comprehensibility and readability of the Articles of Association and include gender-neutral language.
Further proposals include, among others, the re-election of the Independent Proxy and the Statutory Auditors as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Annual Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2022 as well as the Remuneration Report 2022 in a separate consultative vote.
The invitation to the AGM 2023 with the detailed proposals and explanations can be found on the Company’s website.
PolyPeptide Group AG
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.
@PolyPeptide – follow us on LinkedIn
This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.
File: PolyPeptide Group AG_Publication of AGM 2023 Invitation
End of Media Release
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1588541|
|End of News||EQS News Service|